Yasuhisa Sakata

Professor

Saga University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Background Endoscopic phenotypes of pouchitis according to the Chicago Classification have been reported to be associated with poor pouch outcomes in ulcerative colitis (UC). Here, we aimed to assess the prevalence of endoscopic phenotypes and their predictability for pouch outcomes. Methods This retrospective multicenter study included UC patients aged 18 years or older who underwent total colectomy between January 2000 and March 2020. The primary endpoints were frequencies of endoscopic phenotypes of the Chicago Classification and their predictability for chronic pouchitis and pouch failure. Endoscopic findings were evaluated at the initial pouchoscopy and at 3 and 10 years after ileostomy takedown. Results A total of 392 eligible patients were identified. The frequencies of chronic pouchitis and pouch failure were 32% and 4.9%, respectively. Focal inflammation and inlet involvement at the initial postoperative pouchoscopy were significantly associated with subsequent risk of chronic pouchitis and pouch failure, respectively. Thirty percent of the patients with focal inflammation progressed to diffuse inflammation when chronic pouchitis developed. Multivariate analysis showed chronic pouchitis was significantly associated with diffuse inflammation and cuffitis observed throughout the clinical course. The proportion of pouch-related fistula was significantly lower in our cohort than in the US cohort (4.8% vs 19%, P < 0.001), and pouch-related fistula was an independent risk factor for pouch failure. Conclusions We demonstrated the predictability of the Chicago Classification for pouch outcomes, and a lower prevalence of pouch-related fistula, resulting in a lower pouch failure risk in our multicenter cohort.

Year:

2025

Background The over‐the‐scope clip (OTSC) system enables full‐thickness closure of gastrointestinal wall defects and has been used to address gastrointestinal complications of endoscopic and surgical procedures such as perforation, bleeding, and fistulae. This study aimed to evaluate the use of the OTSC system in managing these complications in Saga Prefecture, Japan. Methods We retrospectively analyzed the clinical data of 23 patients who underwent OTSC system‐based management for complications of surgical or endoscopic procedures between January 2020 and July 2024 across five institutions. All procedures were performed by expert endoscopists. Results The mean patient age was 72.3 years and 10 were men. Indications for OTSC treatment included perforation (52.2%), fistula (21.7%), and bleeding (13.0%). Fifteen cases (65.2%) involved the upper gastrointestinal tract. The median duration from the onset of complication to OTSC application was 4 days. OTSC treatment was technically successful in 21 patients (91.3%). Mean procedure time was 39.7 min. Treatment failure occurred in two cases involving jejunal lesions. Seven patients including two technical failures (30.5%) required additional treatment (surgery or repeat OTSC). For patients who required additional intervention, the median duration from OTSC to further treatment was 21 days. The timing of OTSC treatment was not associated with treatment success or the need for further intervention. Conclusions The OTSC system demonstrated a high success rate and favorable safety profile for managing gastrointestinal tract complications. However, early surgical intervention may be required in case OTSC treatment is applied for lesions of deep small bowel or large fibrotic defects.

Year:

2025

Background Most patients take bowel preparation agents at home before undergoing outpatient colonoscopy. However, some elderly patients undergo bowel preparation at the hospital. This study compared the outcomes of in‐hospital (Group A) versus at‐home (Group B) bowel preparation in elderly patients to clarify the usefulness of in‐hospital bowel preparation. Patients and Methods From September 2022 to September 2023, 151 patients aged 70 years or older undergoing outpatient colonoscopy at Ureshino Medical Center were prospectively enrolled (51 in Group A and 100 in Group B). The primary endpoint was bowel preparation time. Secondary endpoints were the number of defecations, colonoscopy start time, and adverse events. Propensity score matching (PSM) was applied to account for baseline differences, and multivariate analysis was conducted to identify factors associated with bowel preparation time. Results After PSM, 26 matched pairs were analyzed. Group A had a significantly shorter bowel preparation time (192.1 ± 80.5 vs. 271.1 ± 57.9 min, p < 0.001), shorter time from preparation to colonoscopy (259.3 ± 70.2 vs. 341.4 ± 67.1 min, p < 0.001), and fewer defecations (8.5 ± 4.6 vs. 11.2 ± 4.1, p < 0.001) than Group B. There were no significant intergroup differences in adverse events or patient satisfaction. Multivariate analysis revealed that in‐hospital preparation was strongly associated with shorter bowel preparation time (odds ratio 8.87, 95% CI 3.16–24.92, p < 0.001). Conclusions For elderly patients, in‐hospital bowel preparation is beneficial because it significantly shortens preparation and colonoscopy start times and reduces defecations, while maintaining safety and satisfaction rates compared with at‐home preparation. Trial Registration: University Hospital Medical Information Network Clinical Trials Registry: UMIN000057045

Year:

2025

Objectives Sedation is increasingly essential for gastrointestinal endoscopy. Remimazolam, an ultra-short-acting benzodiazepine, has a shorter pharmacokinetic half-life than midazolam. The aim of this study was to determine whether remimazolam provides superior procedural sedation in Japanese patients. Methods The cohort of this prospective, multicenter, randomized, single-blind controlled trial comprised adults (18–80 years) scheduled for sedated upper gastrointestinal endoscopy. Participants were randomized to remimazolam and midazolam groups. The primary outcome was the proportion of ambulatory patients 5 min after endoscopy. Secondary outcomes were successful pre-procedure sedation (Modified Observer’s Assessment of Alertness/Sedation ≤ 4), dose of sedative to achieve sedation, time to ambulation, and adverse events. Results From October 2024 to January 2025, 40 patients were enrolled. After excluding two outliers 38 were analyzed (remimazolam, n = 20; midazolam, n = 18). Ambulation at 5 min occurred in 85.0% (17/20) of the remimazolam versus 0.0% (0/18) of the midazolam group ( p < 0.0001). Mean time from procedure end to walking was 4.25 min (range 0.0–10.0) for remimazolam and 35.56 min (10.0–60.0) for midazolam ( p < 0.0001). Pre-procedure sedation was successful (MOAA/S ≤ 4) in 100% of both groups. Mean doses to achieve sedation were 4.30 mg (3.0–7.0) for remimazolam and 3.11 mg (2.0–5.0) for midazolam ( p = 0.003). Hypoxemia occurred in 5.0% of the remimazolam and 33.3% of the midazolam group ( p = 0.038). Conclusions In upper gastrointestinal endoscopy, remimazolam achieved markedly faster recovery and a lower incidence of hypoxemia than midazolam. Rates of achieving target sedation were equivalent. These findings indicate remimazolam is an effective and potentially safer sedative option for Japanese patients undergoing endoscopy. Trial registration : This research was registered with the Japan Registry of Clinical Trials (trial number jRCTs071240062) on September 26, 2024.

Year:

2025

Background Ulcerative colitis (UC) is a heterogeneous disease composed of different endotypes. It is important to develop useful biomarkers for endotyping UC; however, available biomarkers are insufficient. We have already established that periostin is a surrogate biomarker of type 2 inflammation. In this study, we examined the usefulness of periostin as a biomarker of UC and the role of periostin in its pathogenesis. Methods We examined periostin expression in the colons of UC patients. We next investigated serum periostin in UC patients and its correlation with eosinophilic infiltration in their colons. We then examined whether serum periostin could predict the efficacy of oral prednisolone. Finally, we investigated the role of periostin in UC pathogenesis by creating its genetic deficiency using dextran sulfate sodium (DSS)-treated mice. Results Periostin expression and serum periostin were significantly high in UC patients compared to healthy controls; however, both were diverse, showing heterogeneity of the underlying mechanism of UC. Both serum periostin and tissue periostin expression, but not blood eosinophils, were significantly associated with eosinophil infiltration. Type 2-dominant UC patients as defined by serum periostin showed significantly higher clinical remission rates for the treatment with oral prednisolone. Genetic deficiency in periostin improved colonic inflammation in a DSS-treated mouse model. Conclusions Periostin can be a useful biomarker to stratify type 2-dominant UC patients, thereby predicting the efficacy of oral prednisolone. Moreover, periostin plays an important role in the setting of type 2-dominant UC.

Year:

2025

Year:

2025

Background This study evaluated the effectiveness of NUDT15 codon 139 genotyping in optimizing thiopurine treatment for inflammatory bowel disease (IBD) in Japan, using real-world data, and aimed to establish genotype-based treatment strategies. Methods A retrospective analysis of 4628 IBD patients who underwent NUDT15 codon 139 genotyping was conducted. This study assessed the purpose of the genotyping test and subsequent prescriptions following the obtained results. Outcomes were compared between the Genotyping group (thiopurine with genotyping test) and Non-genotyping group (thiopurine without genotyping test). Risk factors for adverse events (AEs) were analyzed by genotype and prior genotyping status. Results Genotyping test for medical purposes showed no significant difference in thiopurine induction rates between Arg/Arg and Arg/Cys genotypes, but nine Arg/Cys patients opted out of thiopurine treatment. In the Genotyping group, Arg/Arg patients received higher initial doses than the Non-genotyping group, while Arg/Cys patients received lower ones (median 25 mg/day). Fewer AEs occurred in the Genotyping group because of their lower incidence in Arg/Cys cases. Starting with < 25 mg/day of AZA reduced AEs in Arg/Cys patients, while Arg/Arg patients had better retention rates when maintaining ≥ 75 mg AZA. Nausea and liver injury correlated with thiopurine formulation but not dosage. pH-dependent mesalamine reduced leukopenia risk in mesalamine users. Conclusions NUDT15 codon 139 genotyping effectively reduces thiopurine-induced AEs and improves treatment retention rates in IBD patients after genotype-based dose adjustments. This study provides data-driven treatment strategies based on genotype and identifies risk factors for specific AEs, contributing to a refined thiopurine treatment approach.

Year:

2024

Objective This study was performed to evaluate whether the use of CAD EYE (Fujifilm, Tokyo, Japan) for colonoscopy improves colonoscopy quality in gastroenterology trainees. Methods The patients in this multicenter randomized controlled trial were divided into Group A (observation using CAD EYE) and Group B (standard observation). Six trainees performed colonoscopies using a back‐to‐back method in pairs with gastroenterology experts. The primary end‐point was the trainees' adenoma detection rate (ADR), and the secondary end‐points were the trainees' adenoma miss rate (AMR) and Assessment of Competency in Endoscopy (ACE) tool scores. Each trainee's learning curve was evaluated using a cumulative sum (CUSUM) control chart. Results We analyzed data for 231 patients (Group A, n = 113; Group B, n = 118). The ADR was not significantly different between the two groups. Group A had a significantly lower AMR (25.6% vs. 38.6%, P = 0.033) and number of missed adenomas per patient (0.5 vs. 0.9, P = 0.004) than Group B. Group A also had significantly higher ACE tool scores for pathology identification (2.26 vs. 2.07, P = 0.030) and interpretation and identification of pathology location (2.18 vs. 2.00, P = 0.038). For the CUSUM learning curve, Group A showed a trend toward a lower number of cases of missed multiple adenomas by the six trainees. Conclusion CAD EYE did not improve ADR but decreased the AMR and improved the ability to accurately locate and identify colorectal adenomas. CAD EYE can be assumed to be beneficial for improving colonoscopy quality in gastroenterology trainees. Trial registration University Hospital Medical Information Network Clinical Trials Registry (UMIN000044031).

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Shintaro Akiyama

University of Tsukuba

JAPAN
View details

Daisuke Yamaguchi

Saga University

JAPAN
View details

Motohiro Esaki

Professor

Saga University

JAPAN
View details